Q4 2024 Oncolytics Biotech Inc Earnings Call Transcript

Mar 07, 2025 / 01:30PM GMT

Release Date Price: $0.6888 (-6.29%)

Transcript

Key Points

Positve

Oncolytics Biotech Inc (ONCY) reported outstanding final data in the BRACELET-1 breast cancer study, exceeding expectations.
The company has promising initial safety and efficacy data in pancreatic and anal cancers from the GOBLET study.
Pelareorep demonstrated a 33% objective response rate in relapsed anal cancer, including a complete response lasting over 15 months.
The company is planning a large Phase 2 study for HR-positive/HER2-negative breast cancer, aiming for accelerated approval.
Oncolytics Biotech Inc (ONCY) has secured a $5 million grant from PanCAN for pancreatic cancer research, indicating strong external support.

Negative

The company is currently without a permanent CEO, which may impact strategic direction and leadership.
Net loss for the fourth quarter of 2024 was $8 million, a significant increase from the previous year's $3.9 million.
The company reported a decrease in cash and cash equivalents, with $15.9 million as of December 31, 2024.
There is uncertainty regarding the total cost and timing of the upcoming registration-enabling trial for metastatic breast cancer.
Oncolytics Biotech Inc (ONCY) faces competition from other oncolytic virus developers, which could impact market positioning and partnerships.

Operator

Good morning, and welcome to Oncolytics Biotech's fourth-quarter and full-year 2024 conference call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead.

Jon Patton

Oncolytics Biotech Inc - Director of Investor Relations and Communication

Thank you, operator. Good morning, everyone, and welcome to Oncolytics fourth-quarter and full-year 2024 earnings call.

As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's mission, strategy, and milestones; the company's belief as to the potential and mechanism of action of pelareorep as a cancer therapeutic; our search for a new permanent CEO; our potential registrational opportunities for pelareorep and our plans and strategies related thereto

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.